Page 111 - MI-1-1

Microbes & Immunity Factors associated with response to T-VEC

doi: 10.1016/j.jamcollsurg.2018.12.027 laherparepvec upregulates immune-cell populations in non-
injected lesions: Findings from a phase II, multicenter, open-
15. Perez MC, Miura JT, Naqvi SM, et al. Talimogene
laherparepvec (TVEC) for the treatment of advanced label study in patients with stage IIIB-IVM1c melanoma.
melanoma: A single-institution experience. Ann Surg Oncol. J Immunother Cancer. 2021;9(3):e001621.
2018;25(13):3960-3965. doi: 10.1136/jitc-2020-001621
doi: 10.1245/s10434-018-6803-0 24. Fazel M, AlRawashdh N, Alamer A, Curiel-Lewandrowski C,
Abraham I. Is there still a role for talimogene laherparepvec
16. Perez MC, Zager JS, Amatruda T, et al. Observational study
of talimogene laherparepvec use for melanoma in clinical (T-VEC) in advanced melanoma? An indirect efficacy
practice in the United States (COSMUS-1). Melanoma comparison of T-VEC plus ipilimumab combination therapy
Manag. 2019;6(2):MMT19. versus T-VEC alone as salvage therapy in unresectable metastatic
melanoma. Expert Opin Biol Ther. 2021;21:1647-1653.
doi: 10.2217/mmt-2019-0012
doi: 10.1080/14712598.2022.1998450
17. Stahlie EH, Franke V, Zuur CL, et al. T-VEC for stage
IIIB-IVM1a melanoma achieves high rates of complete 25. Seremet T, Planken S, Schwarze JK, et al. Successful treatment
with intralesional talimogene laherparepvec in two patients
and durable responses and is associated with tumor load: with immune checkpoint inhibitor-refractory, advanced-
A clinical prediction model. Cancer Immunol Immunother. stage melanoma. Melanoma Res. 2019;29(1):85-88.
2021;70(8):2291-2300.
doi: 10.1097/CMR.0000000000000501
doi: 10.1007/s00262-020-02839-7
26. Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N.
18. Sosman JA, Kim KB, Schuchter L, et al. Survival in Therapeutic efficacy of oncolytic viruses in fighting cancer:
BRAF V600-mutant advanced melanoma treated with Recent advances and perspective. Oxid Med Cell Longev.
vemurafenib. N Engl J Med. 2012;366(8):707-714.
2022;2022:e3142306.
doi: 10.1056/NEJMoa1112302
doi: 10.1155/2022/3142306
19. Long GV, Stroyakovskiy D, Gogas H, et al. Combined 27. Goradel NH, Alizadeh A, Hosseinzadeh S, et al. Oncolytic
BRAF and MEK inhibition versus BRAF inhibition alone in virotherapy as promising immunotherapy against cancer:
melanoma. N Engl J Med. 2014;371(20):1877-1888.
Mechanisms of resistance to oncolytic viruses. Future Oncol.
doi: 10.1056/NEJMoa1406037 2022;18(2):245-259.
20. Steinberg SM, Zhang P, Malik BT, et al. BRAF inhibition doi: 10.2217/fon-2021-0802
alleviates immune suppression in murine autochthonous 28. Jamieson TR, Poutou J, Ilkow CS. Redirecting oncolytic
melanoma. Cancer Immunol Res. 2014;2(11):1044-1050.
viruses: Engineering opportunists to take control of the
doi: 10.1158/2326-6066.CIR-14-0074 tumour microenvironment. Cytokine Growth Factor Rev.
2020;56:102-114.
21. Trojaniello C, Sparano F, Cioli E, Ascierto PA. Sequencing
targeted and immune therapy in BRAF-mutant melanoma: doi: 10.1016/j.cytogfr.2020.07.004
Lessons learned. Curr Oncol Rep. 2023;25(6):623-634.
29. De Matos AL, Franco LS, McFadden G. Oncolytic viruses
doi: 10.1007/s11912-023-01402-8 and the immune system: The dynamic duo. Mol Ther
Methods Clin Dev. 2020;17:349-358.
22. Chesney JA, Puzanov I, Collichio F, et al. Talimogene
laherparepvec (T-VEC) in combination (combo) with doi: 10.1016/j.omtm.2020.01.001
ipilimumab (ipi) versus ipi alone for advanced melanoma: 30. Wang L, Dunmall LS, Cheng Z, Wang Y. Remodeling the
3-year landmark analysis of a randomized, open-label, tumor microenvironment by oncolytic viruses: Beyond
phase II trial. Ann Oncol. 2019;30:v906-v907.
oncolysis of tumor cells for cancer treatment. J Immunother
doi: 10.1093/annonc/mdz394.067 Cancer. 2022;10(5):e004167.
23. Malvehy J, Samoylenko I, Schadendorf D, et al. Talimogene doi: 10.1136/jitc-2021-004167

Volume 1 Issue 1 (2024) 105 doi: 10.36922/mi.3445